Product Code: RP-ID-10293982 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10293982
Market Overview:
Cell Line Development Market, By Products (Reagents and Media, Equipment, and Accessories and Consumables), Sources (Mammalian and Non-Mammalian), Types (Recombinant cell lines, Hybridomas, Continuous cell lines and others), Application (Bioproduction, Drug discovery, Toxicity Testing, and Others) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025
REPORT HIGHLIGHT
The cell line development market is estimated to represent a global market of USD 6.43 billion by 2025 with growth rate of 10.8%. Presence of prominent players who are dedicatedly engaged in cell line development industry will provide healthy platform for the market growth. For example, Lonza’s Cell Culture & Process Development team wide experience in the development of animal cell products such as CHO, hybridomas, various mouse myeloma and human cell lines. This have been used to develop monoclonal antibodies (mAbs) and recombinant proteins using a variety of expression technologies. Furthermore, increasing cancer prevalence is factor leading to the development of market over the forecast period.
Increasing research and development initiatives in oncology area is likely to boost demand for cell lines, leading to market growth. As per the World Health Organizations (WHO), Cancer is considered to be the second leading cause of death worldwide, and was responsible for more than 8.8 million deaths in 2015. Nearly 1 in 6 deaths is due to cancer reported across the globe during the same year. Additionally, rising demand for MAbs-based therapies are considered to be the foremost factors that are anticipated to augment the segment growth.
However, unfavourable regulatory landscape has indirectly pull back the investors of cell line development to invest in this market as regulations play an important role in approval of various products and failure to approve lead to loss for the investor. Also, cell culture or development methods require significant capital investment, cost about USD 250 million to USD 450 million to development and take long three to five years to build. Further, it must be individually approved and certified by the FDA prior to full-scale operation. Such, restrictions will impose the negative growth to the market.
Market is categorized in terms of products such as Reagents and Media, Equipment, and Accessories and Consumables. In terms of equipment, the market is seen as Incubators, Centrifuges, Bioreactors, Storage equipment, and Microscopes. Incubators and bioreactors are collectively accounted for 48.79% share of the global market in 2016 and are expected to dominate the market in future.
Mammalian and non-mammalian are two sources for the cell line development. Among which, mammalian sources are most widely used and considered to be the largest market all the years. In terms of types, the cell line development market is divided as Recombinant cell lines, Hybridomas, Continuous cell lines and others.
Bioproduction, Drug discovery, Toxicity testing, and others are application area for cell line development. Bioproduction recorded more than USD 800.0 million in 2016 and achieve over USD 2 billion during the forecast year. Of which, drug discovery segment is considered to be the least revenue generating application segment owing to the low cost coupled with low preference of it in cell line development.
Regionally, North America dominated the market, captured over 35% share of the global market. Rising research and development activities coupled with increasing number of biotechnology industries in the region helped it to grow consistently. Asia Pacific region is likely to grow with the highest CAGR of 15.2% over the forecast period owing to the favorable government initiatives. Companies such as American Type Culture Collection, Lonza Group, Thermo Fisher Scientific, GE Healthcare, Sigma-Aldrich Corporation, Corning, Inc. and others are operating in this market.
The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment.
The years considered for the study are:
Historical Year – 2014 & 2015
Base Year – 2015
Estimated Year – 2016
Projected Year – 2025
TARGET AUDIENCE
Traders, Distributors, And Suppliers
Manufacturers
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY PRODUCTS
Reagents and Media
Equipment
Accessories and Consumables
MARKET, BY EQUIPMENT
Incubators
Centrifuges
Bioreactors
Storage equipment
Microscopes
MARKET, BY SOURCE
Mammalian
Non mammalian
MARKET, BY TYPES
Recombinant cell lines
Hybridomas
Continuous cell lines
Primary cell lines
MARKET, BY APPLICATION
Bioproduction
Drug discovery
Toxicity testing
Others
MARKET, BY REGION
North America
Europe
Asia Pacific
Rest of the World
MARKET, BY COUNTRY
Further Breakdown of The North America Market
U.S.
Canada
Further Breakdown of The Europe Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle East and Africa
Latin America
Related Reports
Proof of Quality & Reliability
